GENOVIS AB SE-40
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more
GENOVIS AB SE-40 (5GV) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GENOVIS AB SE-40 (5GV) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GENOVIS AB SE-40 - Net Assets Trend (None–None)
This chart illustrates how GENOVIS AB SE-40's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GENOVIS AB SE-40 (None–None)
The table below shows the annual net assets of GENOVIS AB SE-40 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GENOVIS AB SE-40's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GENOVIS AB SE-40 Competitors by Market Cap
The table below lists competitors of GENOVIS AB SE-40 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
All For One Steeb AG
F:A1OS
|
$85.87 Million |
|
Danang Rubber JSC
VN:DRC
|
$85.87 Million |
|
CVWLF
PINK:CVWLF
|
$85.87 Million |
|
Dufu Tech Corp Bhd
KLSE:7233
|
$85.88 Million |
|
CLS HLDGS PLC LS-025
F:838
|
$85.79 Million |
|
Athens Medical C.S.A.
AT:IATR
|
$85.78 Million |
|
EXCO TECHS LTD
F:3XT
|
$85.78 Million |
|
ENB Financial Corp
OTCQX:ENBP
|
$85.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENOVIS AB SE-40's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GENOVIS AB SE-40's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GENOVIS AB SE-40 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GENOVIS AB SE-40's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENOVIS AB SE-40 (5GV) | €- | N/A | N/A | $85.82 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |